NASDAQ:TVGN Tevogen Bio (TVGN) Stock Price, News & Analysis $0.45 +0.03 (+7.21%) (As of 09/10/2024 ET) Add Compare Share Share Today's Range$0.42▼$0.4550-Day Range$0.42▼$0.8052-Week Range$0.40▼$21.09Volume75,205 shsAverage Volume500,466 shsMarket Capitalization$74.14 millionP/E RatioN/ADividend YieldN/APrice Target$4.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Tevogen Bio alerts: Email Address Tevogen Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside841.1% Upside$4.20 Price TargetShort InterestHealthy3.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$2,460 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.01 out of 5 starsMedical Sector319th out of 899 stocksBiological Products, Except Diagnostic Industry43rd out of 154 stocks 3.5 Analyst's Opinion Consensus RatingTevogen Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageTevogen Bio has only been the subject of 1 research reports in the past 90 days.Read more about Tevogen Bio's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.37% of the float of Tevogen Bio has been sold short.Short Interest Ratio / Days to CoverTevogen Bio has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tevogen Bio has recently increased by 28.63%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTevogen Bio does not currently pay a dividend.Dividend GrowthTevogen Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TVGN. Previous Next 0.0 News and Social Media Coverage MarketBeat FollowsOnly 1 people have added Tevogen Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tevogen Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,460.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders56.60% of the stock of Tevogen Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Tevogen Bio's insider trading history. Previous Next N/A Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceFREE TRAINING TODAY ➡️ How to profit from 2024 electionEarlier this year, Millionaire Trader Nate Bear of Monument Traders Alliance went live in front of thousands of traders and placed a unique trade that surged 1,129% in just 2 days... All using a unique trade that cost him less than $0.99 trade.Click here to RSVP to today's FREE training >>> About Tevogen Bio Stock (NASDAQ:TVGN)Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.Read More TVGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TVGN Stock News HeadlinesAugust 22, 2024 | markets.businessinsider.comTevogen Bio Secures $6 Million Series C Preferred Stock InvestmentAugust 15, 2024 | au.finance.yahoo.comWalmart Shares Jump on Q2 Earnings Beat, Guidance RaiseSeptember 11, 2024 | Behind the Markets (Ad)[NOTICE] Your Download Link BelowIf you still haven't downloaded our brand new report: "The Last Retirement Stock You'll Ever Need"...August 15, 2024 | uk.finance.yahoo.comGap between Mag 7, rest of market is 'narrowing' in late 2024August 15, 2024 | globenewswire.comCORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred SharesAugust 15, 2024 | globenewswire.comTevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred SharesAugust 14, 2024 | au.finance.yahoo.comCheck out this $800 rotating VR chair for Meta QuestAugust 14, 2024 | globenewswire.comTevogen Bio's Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public HealthSeptember 11, 2024 | Behind the Markets (Ad)[NOTICE] Your Download Link BelowIf you still haven't downloaded our brand new report: "The Last Retirement Stock You'll Ever Need"...August 12, 2024 | nz.finance.yahoo.comTevogen Bio Holdings Inc. (G28.F)August 9, 2024 | globenewswire.comTevogen Bio's Founding CEO, Ryan Saadi, Expresses Conviction in Company's Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive SecuritiesJuly 28, 2024 | uk.investing.comTevogen Bio Holdings Inc (TVGN)July 11, 2024 | globenewswire.comTevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share BuybackJuly 10, 2024 | globenewswire.comTevogen Bio's R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina AyanianJuly 8, 2024 | globenewswire.comRyan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social ResponsibilityJune 26, 2024 | globenewswire.comTevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive SecuritiesJune 25, 2024 | globenewswire.comTevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood AdvancesJune 18, 2024 | globenewswire.comTevogen.AI Head Discusses Company's Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT ConferenceSee More Headlines Receive TVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tevogen Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TVGN Previous SymbolNASDAQ:TVGN CUSIPN/A CIK1860871 Webwww.semperparatusspac.com Phone913-579-4170FaxN/AEmployees17Year FoundedN/APrice Target and Rating Average Stock Price Target$4.20 High Stock Price Target$4.20 Low Stock Price Target$4.20 Potential Upside/Downside+841.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-387.78% Return on Assets434.75% Debt Debt-to-Equity RatioN/A Current Ratio0.23 Quick Ratio0.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.10) per share Price / Book-0.41Miscellaneous Outstanding Shares166,114,000Free Float72,093,000Market Cap$74.14 million OptionableN/A Beta0.36 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Ryan H. Saadi M.D. (Age 59)M.P.H, M.P.H., Co-Founder, CEO & Chairman Comp: $501kMr. Kirti Desai CPA (Age 67)Chief Financial Officer Comp: $300kDr. Neal Flomenberg M.D. (Age 70)Chief Scientific Officer and Global R&D Lead Comp: $350kMr. Stephen Chen M.B.A.Chief Technical OfficerMr. Mittul MehtaChief Information Officer & Head of Tevogen.aiMr. Tapan V. ShahHead of Investor Relations & Corporate DevelopmentMr. Sadiq Khan M.B.A. (Age 62)Chief Commercial Officer More ExecutivesKey CompetitorsAdaptimmune TherapeuticsNASDAQ:ADAPPoseida TherapeuticsNASDAQ:PSTXMeiraGTxNASDAQ:MGTXSOPHiA GENETICSNASDAQ:SOPHGenfitNASDAQ:GNFTView All CompetitorsInsidersKirti DesaiBought 3,000 shares on 6/12/2024Total: $2,460.00 ($0.82/share)View All Insider Transactions TVGN Stock Analysis - Frequently Asked Questions How have TVGN shares performed this year? Tevogen Bio's stock was trading at $9.51 at the start of the year. Since then, TVGN shares have decreased by 95.3% and is now trading at $0.4463. View the best growth stocks for 2024 here. How do I buy shares of Tevogen Bio? Shares of TVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TVGN) was last updated on 9/11/2024 by MarketBeat.com Staff From Our PartnersFREE TRAINING TODAY ➡️ How to profit from 2024 electionEarlier this year, Millionaire Trader Nate Bear of Monument Traders Alliance went live in front of thousands o...Monument Traders Alliance | SponsoredHow to grow a small trading account into a $100k? Why is Warren Buffett dumping stocks? Billionaires like Warren Buffett, Tim Cook, and Jeff Bezos are offloa...Timothy Sykes | SponsoredKamala's Plan to Bankrupt America—What You Need to KnowWhat if Kamala Wins? The 3 Words That Will Change Everything The same team that predicted Biden’s downfall ...Banyan Hill Publishing | SponsoredWarning For Nvidia HoldersHow The Boeing Disasters Could Hit Nvidia Investors You may have heard about Boeing planes falling apart mi...Stansberry Research | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredYour Crypto Future is at StakeWhat if I told you that bananas could make you a millionaire? No, this isn't a joke – I'm talking about the...Crypto 101 Media | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Bio Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tevogen Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
